222 related articles for article (PubMed ID: 38703250)
21. Precision medicine in head and neck cancer.
Kaidar-Person O; Gil Z; Billan S
Drug Resist Updat; 2018 Sep; 40():13-16. PubMed ID: 30466712
[TBL] [Abstract][Full Text] [Related]
22. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Kurosaki T; Mitani S; Tanaka K; Suzuki S; Kanemura H; Haratani K; Fumita S; Iwasa T; Hayashi H; Yoshida T; Ishikawa K; Kitano M; Otsuki N; Nishimura Y; Doi K; Nakagawa K
Anticancer Drugs; 2021 Jan; 32(1):95-101. PubMed ID: 32976215
[TBL] [Abstract][Full Text] [Related]
24. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
25. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
Hecht M; Eckstein M; Rutzner S; von der Grün J; Illmer T; Klautke G; Laban S; Hautmann MG; Brunner TB; Tamaskovics B; Hinke A; Zhou JG; Frey B; Donaubauer AJ; Becker I; Semrau S; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Gostian AO; Fietkau R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078923
[TBL] [Abstract][Full Text] [Related]
26. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
[TBL] [Abstract][Full Text] [Related]
27. DNA-based immunotherapy for HPV-associated head and neck cancer.
Aggarwal C
Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
[TBL] [Abstract][Full Text] [Related]
28. The value of immunotherapy in head and neck cancer.
Manca P; Raez LE; Salzberg M; Sanchez J; Hunis B; Rolfo C
Expert Opin Biol Ther; 2019 Jan; 19(1):35-43. PubMed ID: 30537444
[TBL] [Abstract][Full Text] [Related]
29. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
30. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Yu Y; Lee NY
Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
[TBL] [Abstract][Full Text] [Related]
31. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
32. Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?
Biau J; Bourhis J
Curr Opin Oncol; 2020 May; 32(3):196-202. PubMed ID: 32251158
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
34. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Moskovitz JM; Moy J; Seiwert TY; Ferris RL
Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
[TBL] [Abstract][Full Text] [Related]
36. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S
Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
39. Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.
Zhang X; Wang P; Chai Y; Zhou X; Li P; Wang X
Am J Otolaryngol; 2024; 45(1):104065. PubMed ID: 37879241
[TBL] [Abstract][Full Text] [Related]
40. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives.
Samra B; Tam E; Baseri B; Shapira I
J Investig Med; 2018 Oct; 66(7):1023-1030. PubMed ID: 29941547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]